LY 3875383
Alternative Names: LY-3875383Latest Information Update: 08 Apr 2024
Price :
$50 *
At a glance
- Originator Eli Lilly and Company
- Class Antihyperlipidaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Hypertriglyceridaemia
Most Recent Events
- 10 Jan 2024 Eli Lilly and Company completes a phase I trial in Hypertriglyceridaemia (In adults, In the elderly) in Singapore (SC) (NCT05609825)
- 10 Jan 2024 Eli Lilly and Company completes a phase I trial in Hypertriglyceridaemia (In volunteers) in Singapore (SC) (NCT05609825)
- 14 Nov 2022 Phase-I clinical trials in Hypertriglyceridaemia (In the elderly, In adults) in Singapore (SC) (NCT05609825; 18537; J4D-MC-EZFA)